• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Chemed (CHE) Stronger Quarterly Earnings

    Simply Wall St·11/06/2026 05:23:56
    Listen to the news
    • Chemed reported third quarter 2026 net income of US$71.65 million versus US$64.24 million a year earlier, with diluted EPS from continuing operations at US$5.45 compared with US$4.46.
    • Across the first nine months of 2026, Chemed’s net income reached US$205.65 million and diluted EPS from continuing operations was US$15.43, both higher than the prior year’s figures and indicating stronger profitability from its hospice and service operations.
    • The next step is to consider how Chemed’s higher diluted EPS from continuing operations could influence the broader investment narrative around the business.
    Capitalize on Chemed's earnings momentum by comparing it with a curated set of resilient healthcare and service providers in the 32 resilient stocks with low risk scores.

    Chemed Investment Narrative Recap

    For a shareholder in Chemed, the core belief is that hospice demand at VITAS and steady plumbing and restoration work at Roto Rooter can support consistent earnings, even when conditions are mixed. The latest quarter’s higher net income and diluted EPS from continuing operations indicate that the operating model is currently holding up across both healthcare and service activities.

    The key short term swing factor remains Medicare reimbursement and Cap exposure in VITAS, because rule or rate changes can quickly affect profitability. In contrast, structurally higher digital lead costs at Roto Rooter still appear to be the main operational risk if pricing and mix cannot keep pace.

    This earnings release itself is the main recent announcement to focus on. Chemed reported third quarter 2026 net income of US$71.65 million, compared with US$64.24 million a year earlier, with diluted EPS from continuing operations at US$5.45, compared with US$4.46. Across the first nine months of 2026, net income was US$205.65 million and diluted EPS from continuing operations was US$15.43.

    Those figures provide a current view of how hospice footprint expansion, Medicare Cap management work, and technology or process improvements at both VITAS and Roto Rooter are affecting the bottom line. They also help frame the trade off between forecast earnings growth, reimbursement exposure, higher customer acquisition costs, and recent insider selling when you compare Chemed with lower risk peers in the healthcare and service space.

    Chemed's current consensus narrative points to revenues of US$3.2b and earnings of US$401.0 million by 2029, based on analysts assuming 7.0% yearly revenue growth and earnings rising by about US$126.0 million from US$275.0 million today.

    Uncover why Chemed's fair value indicates an 11% potential upside to its current price that could narrow quickly.

    NYSE:CHE 1-Year Stock Price Chart
    NYSE:CHE 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate Chemed view focuses on Florida Medicare Cap risk rather than hospice growth. In that more cautious story, the highest analysts were already penciling in US$3.3b of 2029 revenue and US$424.8 million of earnings before this report. This fresh earnings print could push those projections and the gap in opinions in new directions.

    Explore 2 other Chemed fair value estimates, including one that suggests as much as 38% potential upside from the current price.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment outcomes rarely come from following the herd, so rely on your own analysis.

    Looking For More Investment Ideas Beyond Chemed?

    If Chemed's latest earnings update has sharpened your appetite for research, it can help to line it up against other candidates with different risk and return profiles. The Simply Wall St Screener gives you a structured way to do that comparison without getting lost in noise.